- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Environmental Agenda
- Focus on Women's Health
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
Andrew T. Bayman (Andy)
News 40 results
Recognition
October 13, 2021
Benchmark Litigation Recognizes King & Spalding as a Leading Litigation Firm
In the News · Source: Law.com
October 11, 2021
Andy Bayman discusses the use of administrative dockets and registries in the context of the Zantac MDL
Recognition
October 5, 2021
LMG Life Sciences Recognizes King & Spalding With Multiple Rankings in its 2021 Guide
In the News · Source: Law360
October 4, 2021
Andy Bayman represents Boehringer Ingelheim in a Zantac-related dispute before a Florida federal court
Events 6 results
Speaking Engagement
December 7, 2020
Andy Bayman, Kristen Fournier, Adam Spicer to Speak on ACI’s Annual Conference on Drug & Medical Device Litigation
Speaking Engagement
December 9, 2019
Andy Bayman, Geoff Drake, Bobby Woo to Speak at ACI’s Annual Conference on Drug & Medical Device Litigation
Conference
November 12, 2019
12th Annual King & Spalding Pharmaceutical University
Insights 5 results
Article
March 11, 2021
Biden Administration - What's Ahead for the Life Sciences Industry?
COVID-19 Vaccine Updates
March 24, 2020
Tort Immunity under PREP Act and COVID-19 Response Declaration
Client Alert
March 24, 2020
Tort Immunity under PREP Act and COVID-19 Response Declaration
Article · Source: Washington Legal Foundation
March 27, 2015
First Circuit Breathes New Life Into Branded Drug Preemption Defense